AFL — Aflac Incorporated

Sentiment is cautious, not panicked. Q2 2026 adjusted EPS of $1.75 missed consensus by roughly $0.02-$0.03 on FX and lower net investment income, and the stock has pulled back from a July 2026 peak. Analysts are weighted toward Hold (18 Holds, 9 Buys, 5 Sells), with Wolfe initiating at Underperform/Sell and a $103 target, while several banks remain neutral with targets in the $122-$125 area. The consensus target of ~$118.86 implies only modest upside.

The reported quarterly trends are messy and not purely organic. Q3 2024 was a clear outlier with revenue of $3.04B and a net loss of -$93M, which distorts YoY comparisons. More recent reported revenue has been flat-to-down: Q2 2026 revenue of $4.08B fell about 3% YoY, and Q1 2026's 25% rise was flattered by an unusually weak Q1 2025. Operating income fell from $1.225B in Q1 2026 to $0.995B in Q2 2026, while TTM operating margin of 32.2% remains solid but below the strongest prior quarters. Net income swings are heavily influenced by investment gains/losses, so the underlying message is subdued growth, high but compressed profitability, and FX pressure rather than a clean accelerating trend.

Expensive relative to its own history and realistic forward earnings. The TTM P/E of 12.5x looks cheap, but TTM EPS of $9.64 is inflated by non-repeatable investment-timing gains. Consensus normalized forward EPS is about $7.01, which puts the forward P/E near 16.6x versus Aflac's 5-year average P/E of 11.35x. Current P/S of 3.28x is also well above the 5-year average of 2.64x, and P/B of 1.94x is not cheap for an insurer. The PEG ratio is meaningless here because the earnings base is distorted. The stock is carrying a quality/dividend premium that the weak growth and FX drag do not justify.

The market is paying a high multiple on likely forward earnings power, not on trailing reported strength. At $116.58, AFL prices in either a recovery toward normalized EPS above $7.00, continued yen stabilization, or persistent defensive/dividend bid. If normalized EPS stays near $7.00 and FX stays tough, the stock would need to re-rate down or earnings would need to grow back toward $9-$10 to justify the current price at a historical multiple. The stock is essentially asking investors to overlook weak near-term fundamentals for a quality compounder story.

As of 2026-08-27, RSI(14) was 37.96, below 40 but not deeply oversold. The stock was 3.75% below its 20-day SMA and 4.08% below its 50-day SMA, yet still 1.83% above its 200-day SMA. That describes a short/medium-term pullback inside a longer-term uptrend rather than a broken chart. Momentum is negative near-term, and a constructive entry would likely require stabilization above the 20/50-day averages, roughly $117-$121, or a deeper washout to reset sentiment.

• Yen/USD exchange rate: a stronger dollar directly reduces the dollar value of Aflac's Japan-generated profits and has been a recurring EPS headwind.
• Global interest rates: changes in reinvestment yields across Aflac's large fixed-income portfolio affect net investment income and margin trends.
• Defensive/dividend rotation: Aflac's low beta and 42+ year dividend streak attract income/defensive buyers, supporting the multiple even when growth is weak.
• Japan insurance competition and product cycle: third-sector growth in cancer/medical insurance is decelerating, and newer products need to fill the gap.
• Capital-return dynamics: large buybacks and Japan Post Holdings stake sales create offsetting supply and demand forces.

• Q3 2026 earnings, expected late October/early November 2026, with focus on U.S. premium growth and Japan product traction.
• FX reversal: any sustained yen appreciation would mechanically lift dollar-denominated EPS and could reframe the valuation.
• Continued traction from Japan products like Anshin Palette, Miraito, and Tsumitasu, which management expects to push full-year 2026 Japan sales above 2025 levels.
• Potential for accelerated share repurchases if the stock stays below its recent high.

• Japan sales deceleration: core third-sector growth is slowing, and new products may not fully offset competitive/regulatory pressure.
• Further yen weakness: additional USD strength would keep pressuring dollar EPS and make the forward multiple look even more expensive.
• Multiple de-rating: the stock trades around 16.6x forward normalized EPS versus a 5-year average of 11.4x; any growth disappointment could compress the multiple.
• Investment-market volatility: reported earnings are swinging with realized/unrealized investment results, and weaker reinvestment yields are a persistent drag on net investment income.
• Japan Post Holdings automated selling could create share-supply overhang.

Aflac is a high-quality, conservatively financed dividend compounder, but as of 2026-08-27 the stock is paying up for quality. At $116.58, it is ~16.6x normalized forward EPS despite Japan sales declining in local-currency terms, FX pressure, and muted overall growth. The dividend streak and low beta are real assets, but they are already in the price. Until Japan growth reaccelerates or the yen cooperates, the risk/reward skews negative at this valuation.

I applied a justified P/E of approximately 14.5x to normalized forward EPS of $7.01 — a premium to Aflac's 5-year average P/E of 11.35x for its defensive franchise and dividend durability, but below the current ~16.6x forward multiple because growth is subdued and FX is a headwind. A Gordon growth cross-check with D1 of $2.56, required return of 7.5%, and sustainable growth of 5% gives roughly $102, so I set fair value at $101.50.